» Articles » PMID: 29129704

Wearable Activity Monitors in Oncology Trials: Current Use of an Emerging Technology

Overview
Publisher Elsevier
Date 2017 Nov 14
PMID 29129704
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Physical activity is an important outcome in oncology trials. Physical activity is commonly assessed using self-reported questionnaires, which are limited by recall and response biases. Recent advancements in wearable technology have provided oncologists with new opportunities to obtain real-time, objective physical activity data. The purpose of this review was to describe current uses of wearable activity monitors in oncology trials.

Methods: We searched Pubmed, Embase, and the Cochrane Central Register of Controlled Trials for oncology trials involving wearable activity monitors published between 2005 and 2016. We extracted details on study design, types of activity monitors used, and purpose for their use. We summarized activity monitor metrics including step counts, sleep and sedentary time, and time spent in moderate-to-vigorous activity.

Results: We identified 41 trials of which 26 (63%) involved cancer survivors (post-treatment) and 15 trials (37%) involved patients with active cancer. Most trials (65%) involved breast cancer patients. Wearable activity monitors were commonly used in exercise (54%) or behavioral (29%) trials. Cancer survivors take between 4660 and 11,000 steps/day and those undergoing treatment take 2885 to 8300steps/day.

Conclusion: Wearable activity monitors are increasingly being used to obtain objective measures of physical activity in oncology trials. There is potential for their use to expand to evaluate and predict clinical outcomes such as survival, quality of life, and treatment tolerance in future studies. Currently, there remains a lack of standardization in the types of monitors being used and how their data are being collected, analyzed, and interpreted.

Precis: Recent advancements in wearable activity monitor technology have provided oncologists with new opportunities to monitor their patients' daily activity in real-world settings. The integration of wearable activity monitors into cancer care will help increase our understanding of the associations between physical activity and the prevention and management of the disease, in addition to other important cancer outcomes.

Citing Articles

Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model.

Chang P, Hendifar A, Gresham G, Ngo-Huang A, Oberstein P, Parker N Cancers (Basel). 2025; 17(4).

PMID: 40002225 PMC: 11853477. DOI: 10.3390/cancers17040630.


A structured, home-based exercise programme in kidney transplant recipients (ECSERT): A randomised controlled feasibility study.

Billany R, Macdonald J, Burns S, Chowdhury R, Ford E, Mubaarak Z PLoS One. 2025; 20(2):e0316031.

PMID: 39992959 PMC: 11849866. DOI: 10.1371/journal.pone.0316031.


Telemedicine-based exercise intervention in cancer survivors: a non-randomized controlled trial.

Krell V, Porst J, Hafermann L, Kuhn J, Greiss F, Romer C Sci Rep. 2024; 14(1):30615.

PMID: 39715788 PMC: 11666603. DOI: 10.1038/s41598-024-83846-x.


Engagement With Daily Symptom Reporting, Passive Smartphone Sensing, and Wearable Device Data Collection During Chemotherapy: Longitudinal Observational Study.

McClaine S, Fedor J, Bartel C, Chen L, Durica K, Low C JMIR Cancer. 2024; 10:e57347.

PMID: 39656513 PMC: 11668979. DOI: 10.2196/57347.


Big Data for Geriatric Oncology Research.

Duchesneau E, Klepin H, Hanchate A, Lin M, Bluethmann S N C Med J. 2024; 85(1):20-24.

PMID: 39359617 PMC: 11444596. DOI: 10.18043/001c.91420.